TREATMENT OPTIONS IN ONCOLOGY:@0.084848:0.038601:0.493541:0.038601:0.493541:0.019343:0.084848:0.019343:0.010019:0.014276:0.012606:0.015487:0.010019:0.021613:0.012606:0.017404:0.010019:0.006515:0.020438:0.013923:0.010019:0.005315:0.020438:0.017404:0.011712:0.006515:0.005315:0.017404:0.006515:0.020438:0.017404:0.019121:0.020438:0.010866:0.020438:0.020508:0.013923
30:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
rituximab alone or Zevalin. The overall re-:@0.084848:0.096166:0.475756:0.096166:0.475756:0.080410:0.084848:0.080410:0.005600:0.003656:0.006331:0.011507:0.009044:0.003656:0.017857:0.012950:0.012931:0.008428:0.012950:0.003656:0.012411:0.011545:0.012315:0.008428:0.012411:0.005600:0.008428:0.009044:0.012315:0.010468:0.012950:0.003656:0.003656:0.011545:0.005138:0.008428:0.008005:0.011545:0.012315:0.008428:0.012411:0.010468:0.012315:0.005600:0.012950:0.003656:0.003656:0.008428:0.005521:0.012315:0.006388
sponse rate was 80% for Zevalin, compared :@0.084848:0.112345:0.481067:0.112345:0.481067:0.096589:0.084848:0.096589:0.007274:0.012931:0.012411:0.011545:0.007274:0.012315:0.004368:0.005600:0.012950:0.006331:0.012315:0.004368:0.015798:0.012950:0.007274:0.004368:0.010468:0.010468:0.014720:0.004368:0.005850:0.012411:0.005600:0.004368:0.009044:0.012315:0.010468:0.012950:0.003656:0.003656:0.011545:0.005138:0.004368:0.012257:0.012411:0.017857:0.012931:0.012950:0.005519:0.012315:0.013183:0.005330
with 56% with rituximab alone.:@0.084848:0.128524:0.357455:0.128524:0.357455:0.112768:0.084848:0.112768:0.015798:0.003656:0.006331:0.011545:0.005138:0.010468:0.010468:0.014720:0.005138:0.015798:0.003656:0.006331:0.011545:0.005138:0.005600:0.003656:0.006331:0.011507:0.009044:0.003656:0.017857:0.012950:0.012931:0.005138:0.012950:0.003656:0.012411:0.011545:0.012315:0.005330
15:@0.357254:0.122909:0.369572:0.122909:0.369572:0.113723:0.357254:0.113723:0.006103:0.006215
Bone-marrow suppression is a potential :@0.103030:0.144709:0.481090:0.144709:0.481090:0.128953:0.103030:0.128953:0.011045:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005707:0.012604:0.015990:0.008014:0.007466:0.011699:0.013123:0.013123:0.005717:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.008024:0.003848:0.007466:0.008024:0.013143:0.008024:0.013123:0.012604:0.006523:0.012508:0.011738:0.006523:0.003848:0.013143:0.003848:0.005330
side effect  of  therapy  with Zevalin and :@0.084846:0.160888:0.481088:0.160888:0.481088:0.145132:0.084846:0.145132:0.007466:0.003848:0.013181:0.012508:0.010814:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.005330:0.005473:0.012604:0.006042:0.005330:0.005474:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005473:0.015990:0.003848:0.006523:0.011738:0.010814:0.009236:0.012508:0.010660:0.013143:0.003848:0.003848:0.011738:0.010814:0.013143:0.011738:0.013181:0.005330
this may persist for up to 12  weeks post-:@0.084846:0.177068:0.475731:0.177068:0.475731:0.161312:0.084846:0.161312:0.006523:0.011738:0.003848:0.007466:0.008640:0.018049:0.013143:0.010314:0.008640:0.013123:0.012508:0.005792:0.007466:0.003848:0.007466:0.006523:0.008640:0.006042:0.012604:0.005792:0.008640:0.011699:0.013123:0.008640:0.006523:0.012604:0.008640:0.010660:0.010660:0.005330:0.003323:0.015990:0.012508:0.012508:0.009660:0.007466:0.008640:0.013123:0.012604:0.007466:0.006523:0.006388
treatment.  Patients  should  therefore  be :@0.084846:0.193247:0.481090:0.193247:0.481090:0.177491:0.084846:0.177491:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005330:0.006464:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.006475:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330:0.006475:0.006523:0.011738:0.012508:0.005707:0.012508:0.006042:0.012604:0.005707:0.012508:0.005330:0.006473:0.013123:0.012508:0.005330
followed-up with weekly full blood count :@0.084846:0.209426:0.481067:0.209426:0.481067:0.193670:0.084846:0.193670:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.006388:0.011699:0.013123:0.008063:0.015990:0.003848:0.006523:0.011738:0.008063:0.015990:0.012508:0.012508:0.009660:0.003848:0.010314:0.008063:0.006042:0.011699:0.003848:0.003848:0.008063:0.013123:0.003848:0.012604:0.012604:0.013181:0.008063:0.012450:0.012604:0.011699:0.011738:0.006523:0.005330
until recovery.:@0.084846:0.225605:0.215710:0.225605:0.215710:0.209849:0.084846:0.209849:0.011699:0.011738:0.006523:0.003848:0.003848:0.005330:0.005711:0.012508:0.012450:0.012604:0.010660:0.012508:0.005792:0.010314:0.005330
CONCLUSION:@0.084848:0.258623:0.240070:0.258623:0.240070:0.239027:0.084848:0.239027:0.018344:0.019756:0.017404:0.018344:0.010348:0.015052:0.012230:0.006585:0.019756:0.017404
Nuclear medicine is in a prime position :@0.084848:0.277098:0.481105:0.277098:0.481105:0.261342:0.084848:0.261342:0.014432:0.011892:0.012642:0.004041:0.012700:0.013335:0.005984:0.009640:0.018242:0.012700:0.013373:0.004041:0.012642:0.004041:0.011930:0.012700:0.009640:0.004041:0.007658:0.009640:0.004041:0.011930:0.009640:0.013335:0.009640:0.013316:0.005984:0.004041:0.018242:0.012700:0.009640:0.013316:0.012796:0.007658:0.004041:0.006716:0.004041:0.012796:0.011736:0.005330
to utilise personalised care in cancer :@0.084848:0.293277:0.481101:0.293277:0.481101:0.277521:0.084848:0.277521:0.006716:0.012796:0.014239:0.011892:0.006716:0.004041:0.004041:0.004041:0.007658:0.012700:0.014239:0.013316:0.012700:0.005984:0.007658:0.012796:0.011930:0.013335:0.004041:0.004041:0.007658:0.012700:0.013373:0.014239:0.012642:0.013335:0.005905:0.012700:0.014239:0.004041:0.011930:0.014239:0.012642:0.013335:0.011930:0.012642:0.012700:0.005788:0.005330
management. Targeted therapy ensures :@0.084848:0.309456:0.481105:0.309456:0.481105:0.293700:0.084848:0.293700:0.018242:0.013335:0.011930:0.013335:0.013143:0.012700:0.018242:0.012700:0.011930:0.006716:0.005523:0.007678:0.007389:0.013335:0.006000:0.013143:0.012700:0.006716:0.012700:0.013373:0.007678:0.006716:0.011930:0.012700:0.005984:0.013335:0.013316:0.010506:0.007678:0.012700:0.011930:0.007658:0.011892:0.005905:0.012700:0.007470:0.005330
that a disease is seen, and a determina-:@0.084848:0.325635:0.475750:0.325635:0.475750:0.309880:0.084848:0.309880:0.006716:0.011930:0.013335:0.006716:0.006754:0.013335:0.006754:0.013373:0.004041:0.007658:0.012700:0.013335:0.007658:0.012700:0.006754:0.004041:0.007658:0.006754:0.007658:0.012700:0.012700:0.011930:0.005523:0.006754:0.013335:0.011930:0.013373:0.006754:0.013335:0.006754:0.013373:0.012700:0.006716:0.012700:0.006515:0.018242:0.004041:0.011930:0.013335:0.006388
tion is made as to whether the disease :@0.084848:0.341815:0.481067:0.341815:0.481067:0.326059:0.084848:0.326059:0.006716:0.004041:0.012796:0.011930:0.009256:0.004041:0.007658:0.009256:0.018242:0.013335:0.013373:0.012700:0.009256:0.013335:0.007658:0.009256:0.006716:0.012796:0.009256:0.016183:0.011930:0.012700:0.006716:0.011930:0.012700:0.005984:0.009256:0.006716:0.011930:0.012700:0.009256:0.013373:0.004041:0.007658:0.012700:0.013335:0.007658:0.012506:0.005330
will respond to therapy; only then is tar-:@0.084848:0.357994:0.475754:0.357994:0.475754:0.342238:0.084848:0.342238:0.016183:0.004041:0.004041:0.004041:0.008390:0.005904:0.012700:0.007658:0.013316:0.012796:0.011930:0.013373:0.008390:0.006716:0.012796:0.008390:0.006716:0.011930:0.012700:0.005984:0.013335:0.013316:0.010506:0.005523:0.008390:0.012796:0.011930:0.004041:0.010506:0.008390:0.006716:0.011930:0.012700:0.011930:0.008390:0.004041:0.007658:0.008390:0.006716:0.013335:0.005984:0.006388
geted radionuclide therapy embarked :@0.084848:0.374173:0.481090:0.374173:0.481090:0.358417:0.084848:0.358417:0.013143:0.012700:0.006716:0.012700:0.013373:0.012777:0.005984:0.013335:0.013373:0.004041:0.012796:0.011930:0.011892:0.012642:0.004041:0.004041:0.013373:0.012700:0.012777:0.006716:0.011930:0.012700:0.005984:0.013335:0.013316:0.010506:0.012777:0.012700:0.018242:0.013316:0.013335:0.005984:0.009852:0.012700:0.013183:0.005330
upon. This ensures that treatment is only :@0.084848:0.390353:0.481146:0.390353:0.481146:0.374597:0.084848:0.374597:0.011892:0.013316:0.012796:0.011930:0.005523:0.008101:0.008390:0.011930:0.004041:0.007658:0.008101:0.012700:0.011930:0.007658:0.011892:0.005905:0.012700:0.007658:0.008101:0.006716:0.011930:0.013335:0.006716:0.008101:0.006716:0.005905:0.012700:0.013335:0.006716:0.018242:0.012700:0.011930:0.006716:0.008101:0.004041:0.007658:0.008101:0.012796:0.011930:0.004041:0.010318:0.005330
offered to patients who will benefit from :@0.084848:0.406532:0.481111:0.406532:0.481111:0.390776:0.084848:0.390776:0.012796:0.006290:0.006235:0.012700:0.005904:0.012700:0.013373:0.007647:0.006716:0.012796:0.007647:0.013316:0.013335:0.006716:0.004041:0.012700:0.011930:0.006716:0.007658:0.007649:0.016183:0.011930:0.012796:0.007647:0.016183:0.004041:0.004041:0.004041:0.007647:0.013316:0.012700:0.011930:0.012700:0.004782:0.004782:0.006716:0.007649:0.006235:0.005905:0.012796:0.018049:0.005330
it, prevents unnecessary adverse effects :@0.084848:0.422711:0.481088:0.422711:0.481088:0.406955:0.084848:0.406955:0.004041:0.006716:0.005523:0.008140:0.013316:0.005905:0.012700:0.010853:0.012700:0.011930:0.006716:0.007658:0.008140:0.011892:0.011930:0.011930:0.012700:0.012642:0.012700:0.007658:0.007658:0.013335:0.005984:0.010506:0.008140:0.013335:0.013373:0.010853:0.012700:0.005984:0.007658:0.012700:0.008140:0.012700:0.006290:0.006235:0.012700:0.012642:0.006716:0.007470:0.005330
and saves cost. The spectrum of cancers :@0.084848:0.438890:0.481092:0.438890:0.481092:0.423134:0.084848:0.423134:0.013335:0.011930:0.013373:0.006138:0.007658:0.013335:0.010853:0.012700:0.007658:0.006138:0.012642:0.012796:0.007658:0.006716:0.005523:0.006138:0.008390:0.011930:0.012700:0.006138:0.007658:0.013316:0.012700:0.012642:0.006716:0.005984:0.011892:0.018242:0.006138:0.012796:0.006235:0.006138:0.012642:0.013335:0.011930:0.012642:0.012700:0.005984:0.007470:0.005330
that can be treated with this technique is :@0.084848:0.455070:0.481088:0.455070:0.481088:0.439314:0.084848:0.439314:0.006716:0.011930:0.013335:0.006716:0.005465:0.012642:0.013335:0.011930:0.005465:0.013316:0.012700:0.005465:0.006716:0.005905:0.012700:0.013335:0.006716:0.012700:0.013373:0.005465:0.016183:0.004041:0.006716:0.011930:0.005465:0.006716:0.011930:0.004041:0.007658:0.005465:0.006716:0.012700:0.012642:0.011930:0.011930:0.004041:0.013316:0.011892:0.012700:0.005465:0.004041:0.007468:0.005330
widening, with an increasing number of :@0.084848:0.471249:0.481084:0.471249:0.481084:0.455493:0.084848:0.455493:0.016183:0.004041:0.013373:0.012700:0.011930:0.004041:0.011930:0.013143:0.005523:0.008736:0.016183:0.004041:0.006716:0.011930:0.008736:0.013335:0.011930:0.008736:0.004041:0.011930:0.012642:0.005905:0.012700:0.013335:0.007658:0.004041:0.011930:0.013143:0.008736:0.011930:0.011892:0.018242:0.013316:0.012700:0.005984:0.008736:0.012796:0.006040:0.005330
biological  targets  with  potential  for  use :@0.084848:0.487428:0.481090:0.487428:0.481090:0.471672:0.084848:0.471672:0.013316:0.004041:0.012796:0.004041:0.012796:0.013143:0.004041:0.012642:0.013335:0.004041:0.005330:0.004455:0.006716:0.013335:0.005998:0.013143:0.012700:0.006716:0.007658:0.005330:0.004455:0.016183:0.004041:0.006716:0.011930:0.005330:0.004455:0.013316:0.012796:0.006716:0.012700:0.011930:0.006716:0.004041:0.013335:0.004041:0.005330:0.004455:0.006235:0.012796:0.005984:0.005330:0.004455:0.011892:0.007658:0.012506:0.005330
in developing therapeutic radiopharma-:@0.084848:0.503607:0.475750:0.503607:0.475750:0.487852:0.084848:0.487852:0.004041:0.011930:0.007158:0.013373:0.012700:0.010853:0.012700:0.004041:0.012796:0.013316:0.004041:0.011930:0.013143:0.007158:0.006716:0.011930:0.012700:0.005984:0.013335:0.013316:0.012700:0.011892:0.006716:0.004041:0.012642:0.007158:0.005984:0.013335:0.013373:0.004041:0.012796:0.013316:0.011930:0.013335:0.006515:0.018242:0.013335:0.006388
ceuticals for treatment.:@0.084848:0.519787:0.306865:0.519787:0.306865:0.504031:0.084848:0.504031:0.012642:0.012700:0.011892:0.006716:0.004041:0.012642:0.013335:0.004041:0.007658:0.005523:0.006235:0.012796:0.005984:0.005523:0.006716:0.005905:0.012700:0.013335:0.006716:0.018242:0.012700:0.011930:0.006716:0.005330
REFERENCES:@0.084848:0.549208:0.195685:0.549208:0.195685:0.533175:0.084848:0.533175:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084848:0.565976:0.103800:0.565976:0.103800:0.551971:0.084848:0.551971:0.009476:0.004738:0.004738
 Jadvar H. Targeted radionuclide therapy: :@0.121195:0.565976:0.480503:0.565976:0.480503:0.551971:0.121195:0.551971:0.000000:0.008244:0.011682:0.011716:0.009476:0.011682:0.005148:0.007800:0.011682:0.004738:0.007800:0.006397:0.011682:0.005162:0.011511:0.011118:0.005798:0.011118:0.011716:0.007800:0.005148:0.011682:0.011716:0.003421:0.011203:0.010434:0.010399:0.011067:0.003421:0.003421:0.011716:0.011118:0.007800:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
an evolution toward precision cancer :@0.121195:0.580099:0.480525:0.580099:0.480525:0.566094:0.121195:0.566094:0.011682:0.010434:0.015445:0.011118:0.009476:0.011203:0.003421:0.010399:0.005798:0.003421:0.011203:0.010434:0.015445:0.005798:0.011203:0.014214:0.011682:0.005047:0.011716:0.015445:0.011665:0.005080:0.011118:0.011067:0.003421:0.006636:0.003421:0.011203:0.010434:0.015445:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
treatment. :@0.121195:0.594222:0.213536:0.594222:0.213536:0.580217:0.121195:0.580217:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738
AJR. :@0.213524:0.594222:0.254284:0.594222:0.254284:0.580217:0.213524:0.580217:0.012657:0.008244:0.010382:0.004738:0.004738
2017;209:277-288.:@0.254267:0.594222:0.397345:0.594222:0.397345:0.580217:0.254267:0.580217:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
2. :@0.084848:0.608345:0.103461:0.608345:0.103461:0.594340:0.084848:0.594340:0.009479:0.004396:0.004738
  Lawal I, :@0.121197:0.608345:0.187640:0.608345:0.187640:0.594340:0.121197:0.594340:0.004738:-0.004738:0.007560:0.011340:0.013872:0.011340:0.003079:0.006595:0.003523:0.004396:0.004738
et al:@0.189493:0.608345:0.227088:0.608345:0.227088:0.594340:0.189493:0.594340:0.010776:0.005456:0.006602:0.011340:0.003421
. Gallium-68-dotatate PET/CT is :@0.226746:0.608345:0.480510:0.608345:0.480510:0.594340:0.226746:0.594340:0.004396:0.006602:0.014573:0.011340:0.003079:0.003079:0.003079:0.010057:0.015702:0.005337:0.009134:0.009134:0.005337:0.011374:0.010861:0.005456:0.011340:0.005456:0.011340:0.005456:0.010776:0.006602:0.009784:0.008826:0.006944:0.007133:0.013564:0.006944:0.006602:0.003079:0.006640:0.004738
better than CT in the management of soma-:@0.121195:0.622468:0.475789:0.622468:0.475789:0.608463:0.121195:0.608463:0.011323:0.010776:0.005456:0.005456:0.010776:0.004806:0.004401:0.005456:0.010092:0.011340:0.010092:0.004403:0.013564:0.006944:0.004401:0.003079:0.010092:0.004401:0.005456:0.010092:0.010776:0.004401:0.015702:0.011340:0.010092:0.011340:0.011169:0.010776:0.015702:0.010776:0.010092:0.005456:0.004401:0.010861:0.005029:0.004401:0.006294:0.010861:0.015702:0.011340:0.005679
tostatin expressing tumors: first experience in :@0.121195:0.636591:0.480517:0.636591:0.480517:0.622585:0.121195:0.622585:0.005456:0.010861:0.006294:0.005456:0.011340:0.005456:0.003079:0.010092:0.005504:0.010776:0.007868:0.011323:0.004736:0.010776:0.006294:0.006294:0.003079:0.010092:0.011169:0.005504:0.005456:0.010057:0.015702:0.010861:0.004806:0.006294:0.004396:0.005502:0.003994:0.003994:0.004806:0.006294:0.005456:0.005504:0.010776:0.007868:0.011323:0.010776:0.004806:0.003079:0.010776:0.010092:0.010724:0.010776:0.005504:0.003079:0.010430:0.004738
Africa. :@0.121195:0.650714:0.177622:0.650714:0.177622:0.636708:0.121195:0.636708:0.012315:0.005029:0.004806:0.003079:0.010724:0.011340:0.004396:0.004738
Hell J Nucl Med. :@0.177263:0.650714:0.309463:0.650714:0.309463:0.636708:0.177263:0.636708:0.011340:0.010776:0.003079:0.003079:0.004396:0.007902:0.004396:0.012315:0.010057:0.010724:0.003079:0.004396:0.015377:0.010776:0.011374:0.004396:0.004738
2017;20:128-133.:@0.309121:0.650714:0.437592:0.650714:0.437592:0.636708:0.309121:0.636708:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.004738
3. :@0.084848:0.664836:0.103800:0.664836:0.103800:0.650831:0.084848:0.650831:0.009476:0.004738:0.004738
 Strosberg J, :@0.121195:0.664836:0.219851:0.664836:0.219851:0.650831:0.121195:0.650831:0.000000:0.008518:0.005798:0.005077:0.011203:0.006636:0.011665:0.011118:0.005160:0.011511:0.004249:0.008244:0.004738:0.004738
et al:@0.219357:0.664836:0.255625:0.664836:0.255625:0.650831:0.219357:0.650831:0.011118:0.005798:0.004249:0.011682:0.003421
. Phase 3 Trial of  Lu-Dota-:@0.255625:0.664836:0.475761:0.664839:0.475761:0.650834:0.255625:0.650831:0.004738:0.004249:0.010126:0.010434:0.011682:0.006636:0.011118:0.004247:0.009476:0.004259:0.006773:0.005148:0.003421:0.011682:0.003421:0.004259:0.011203:0.005371:0.004738:0.016086:0.007902:0.010399:0.005679:0.012726:0.011203:0.005798:0.011682:0.037796
177:@0.388113:0.659844:0.404686:0.659844:0.404686:0.651679:0.388113:0.651679:0.005524:0.005524:0.005524
tate for midgut neuroendocrine tumors. :@0.121187:0.678962:0.461237:0.678962:0.461237:0.664957:0.121187:0.664957:0.005798:0.011682:0.005798:0.011118:0.006619:0.005371:0.011203:0.005148:0.006609:0.016044:0.003421:0.011716:0.011511:0.010399:0.005798:0.006619:0.010434:0.011118:0.010399:0.005071:0.011203:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.006602:0.005798:0.010399:0.016044:0.011203:0.005148:0.006636:0.004738:0.004738
N :@0.463104:0.678962:0.480499:0.678962:0.480499:0.664957:0.463104:0.664957:0.012657:0.004738
Engl J Med.:@0.121187:0.693085:0.216732:0.693085:0.216732:0.679079:0.121187:0.679079:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716:0.004738
 2017;376:125-135.:@0.216715:0.693085:0.364531:0.693085:0.364531:0.679079:0.216715:0.679079:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
4. :@0.084841:0.707208:0.103792:0.707208:0.103792:0.693202:0.084841:0.693202:0.009476:0.004738:0.004738
  Janson ET, Oberg K. Long-term manage-:@0.121187:0.707208:0.475754:0.707208:0.475754:0.693202:0.121187:0.693202:0.004738:-0.004738:0.008244:0.011682:0.010434:0.006636:0.011203:0.010434:0.008775:0.009168:0.005540:0.004738:0.008775:0.014864:0.011665:0.011118:0.005162:0.011511:0.008775:0.010109:0.004738:0.008775:0.007902:0.011203:0.010434:0.011511:0.005679:0.005798:0.011104:0.005622:0.016044:0.008775:0.016044:0.011682:0.010434:0.011682:0.011511:0.011118:0.005679
ment  of the  carcinoid syndrome:  treat-:@0.121187:0.721330:0.475766:0.721330:0.475766:0.707325:0.121187:0.707325:0.016044:0.011118:0.010434:0.005798:0.004738:0.006643:0.011203:0.005371:0.011392:0.005798:0.010434:0.011118:0.004738:0.006643:0.011067:0.011682:0.005030:0.011067:0.003421:0.010434:0.011203:0.003421:0.011716:0.011392:0.006636:0.009168:0.010434:0.011716:0.005082:0.011203:0.016044:0.011118:0.004738:0.004738:0.006645:0.005798:0.005077:0.011118:0.011682:0.005798:0.005679
ment with octreotide alone and in combi-:@0.121187:0.735453:0.475776:0.735453:0.475776:0.721448:0.121187:0.721448:0.016044:0.011118:0.010434:0.005798:0.005857:0.014214:0.003421:0.005798:0.010434:0.005867:0.011203:0.011067:0.005798:0.005071:0.011118:0.011203:0.005798:0.003421:0.011716:0.011118:0.005867:0.011682:0.003421:0.011203:0.010434:0.011118:0.005867:0.011682:0.010434:0.011716:0.005867:0.003421:0.010434:0.005867:0.011067:0.011203:0.016044:0.011665:0.003421:0.005679
nation  with  alpha-interferon. :@0.121187:0.749576:0.367781:0.749576:0.367781:0.735571:0.121187:0.735571:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.003151:0.014214:0.003421:0.005798:0.010434:0.004738:0.003156:0.011682:0.003421:0.011665:0.010434:0.011682:0.005679:0.003421:0.010434:0.005798:0.011118:0.005963:0.005371:0.011118:0.005075:0.011203:0.010434:0.004738:0.004738
Acta Oncol.:@0.370928:0.749576:0.475761:0.749576:0.475761:0.735571:0.370928:0.735571:0.012657:0.011067:0.005798:0.011682:0.007902:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.475761:0.749576:0.480499:0.749576:0.480499:0.735571:0.475761:0.735571:0.004738
1993;32:225-229.:@0.121187:0.763699:0.253543:0.763699:0.253543:0.749694:0.121187:0.749694:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.008229:0.004738
5. :@0.524235:0.094738:0.543186:0.094738:0.543186:0.080733:0.524235:0.080733:0.009476:0.004738:0.004738
  Ducreux M, :@0.560581:0.094738:0.660204:0.094738:0.660204:0.080733:0.560581:0.080733:0.004738:-0.004738:0.012726:0.010399:0.011067:0.005078:0.011118:0.010399:0.008210:0.005431:0.015719:0.004738:0.004738
et al:@0.660898:0.094738:0.698357:0.094738:0.698357:0.080733:0.660898:0.080733:0.011118:0.005798:0.005439:0.011682:0.003421
. The antitumoral effect of :@0.698357:0.094738:0.919901:0.094738:0.919901:0.080733:0.698357:0.080733:0.004738:0.005439:0.007286:0.010434:0.011118:0.005427:0.011682:0.010434:0.005798:0.003421:0.005798:0.010399:0.016044:0.011203:0.005148:0.011682:0.003421:0.005439:0.011118:0.005417:0.005371:0.011118:0.011067:0.005798:0.005431:0.011203:0.005371:0.004738
the  long-acting somatostatin analog lan-:@0.560581:0.108967:0.915162:0.108967:0.915162:0.094962:0.560581:0.094962:0.005798:0.010434:0.011118:0.004738:0.003650:0.003421:0.011203:0.010434:0.011511:0.005679:0.011682:0.011067:0.005798:0.003421:0.010434:0.011511:0.008398:0.006636:0.011203:0.016044:0.011682:0.005798:0.011203:0.006636:0.005798:0.011682:0.005798:0.003421:0.010434:0.008398:0.011682:0.010434:0.011682:0.003421:0.011203:0.011511:0.008398:0.003421:0.011682:0.010434:0.005679
reotide  in  neuroendocrine  tumors. :@0.560581:0.123196:0.862755:0.123196:0.862755:0.109190:0.560581:0.109190:0.005078:0.011118:0.011203:0.005798:0.003421:0.011716:0.011118:0.004738:0.005355:0.003421:0.010434:0.004738:0.005362:0.010434:0.011118:0.010399:0.005071:0.011203:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.004738:0.005345:0.005798:0.010399:0.016044:0.011203:0.005148:0.006636:0.004738:0.004738
Am  J :@0.868101:0.123196:0.919877:0.123196:0.919877:0.109190:0.868101:0.109190:0.012657:0.016044:0.004738:0.005355:0.008244:0.004738
Gastroenterol. :@0.560581:0.137424:0.683681:0.137424:0.683681:0.123419:0.560581:0.123419:0.014915:0.011682:0.006636:0.005798:0.005148:0.011203:0.011118:0.010434:0.005798:0.011118:0.005148:0.011203:0.003421:0.004738:0.004738
2000;95:3276-3281.:@0.683664:0.137424:0.836218:0.137424:0.836218:0.123419:0.683664:0.123419:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
6. :@0.524235:0.151653:0.543186:0.151653:0.543186:0.137648:0.524235:0.137648:0.009476:0.004738:0.004738
  Pavel ME, :@0.560581:0.151653:0.646893:0.151653:0.646893:0.137648:0.560581:0.137648:0.004738:-0.004738:0.010126:0.011682:0.009476:0.011118:0.003421:0.006127:0.015719:0.009168:0.004738:0.004738
et al:@0.648275:0.151653:0.686418:0.151653:0.686418:0.137648:0.648275:0.137648:0.011118:0.005798:0.006123:0.011682:0.003421
. Everolimus plus octreotide :@0.686418:0.151653:0.919869:0.151653:0.919869:0.137648:0.686418:0.137648:0.004738:0.006123:0.009168:0.009476:0.011118:0.005082:0.011203:0.003421:0.003421:0.016044:0.010399:0.006636:0.006123:0.011665:0.003421:0.010399:0.006636:0.006123:0.011203:0.011067:0.005798:0.005071:0.011118:0.011203:0.005798:0.003421:0.011716:0.011118:0.004738
long-acting  repeatable for  the  treatment :@0.560581:0.165882:0.919893:0.165882:0.919893:0.151877:0.560581:0.151877:0.003421:0.011203:0.010434:0.011511:0.005679:0.011682:0.011067:0.005798:0.003421:0.010434:0.011511:0.004738:0.003291:0.005078:0.011118:0.011665:0.011118:0.011682:0.005798:0.011682:0.011665:0.003421:0.011118:0.008039:0.005371:0.011203:0.005148:0.004738:0.003291:0.005798:0.010434:0.011118:0.004738:0.003291:0.005798:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
of advanced neuroendocrine  tumors as-:@0.560581:0.180111:0.915139:0.180111:0.915139:0.166105:0.560581:0.166105:0.011203:0.005371:0.008997:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.008997:0.010434:0.011118:0.010399:0.005077:0.011203:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.004738:0.004247:0.005798:0.010399:0.016044:0.011203:0.005148:0.006636:0.008997:0.011682:0.006636:0.005679
sociated with carcinoid syndrome (RADI-:@0.560581:0.194339:0.915139:0.194339:0.915139:0.180334:0.560581:0.180334:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.011118:0.011716:0.008997:0.014214:0.003421:0.005798:0.010434:0.008997:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.003421:0.011716:0.008997:0.006636:0.009168:0.010434:0.011716:0.005082:0.011203:0.016044:0.011118:0.008997:0.006312:0.010382:0.012657:0.012726:0.003866:0.005679
ANT-2): a randomized, placebo-controlled, :@0.560581:0.208568:0.919882:0.208568:0.919882:0.194563:0.560581:0.194563:0.012657:0.012657:0.007286:0.005679:0.009476:0.006312:0.004738:0.004295:0.011682:0.004302:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.004738:0.004300:0.011665:0.003421:0.011682:0.011067:0.011118:0.011665:0.011203:0.005679:0.011067:0.011203:0.010434:0.005798:0.005070:0.011203:0.003421:0.003421:0.011118:0.011716:0.004738:0.004738
phase 3 study. :@0.560581:0.222797:0.684263:0.222797:0.684263:0.208791:0.560581:0.208791:0.011665:0.010434:0.011682:0.006636:0.011118:0.004738:0.009476:0.004738:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Lancet. :@0.684263:0.222797:0.751740:0.222797:0.751740:0.208791:0.684263:0.208791:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738:0.004738
2014;378:2005-2012.:@0.751723:0.222797:0.913752:0.222797:0.913752:0.208791:0.751723:0.208791:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
7. :@0.524235:0.237025:0.543186:0.237025:0.543186:0.223020:0.524235:0.223020:0.009476:0.004738:0.004738
  Bodei  L, :@0.560581:0.237025:0.637031:0.237025:0.637031:0.223020:0.560581:0.223020:0.004738:-0.004738:0.009818:0.011203:0.011716:0.011118:0.003421:0.004738:0.007057:0.007902:0.004738:0.004738
et  al:@0.644085:0.237025:0.687892:0.237025:0.687892:0.223020:0.644085:0.223020:0.011118:0.005798:0.004738:0.007050:0.011682:0.003421
.  Long-term  tolerability of :@0.687892:0.237025:0.919898:0.237025:0.919898:0.223020:0.687892:0.223020:0.004738:0.004738:0.007061:0.007902:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005607:0.016044:0.004738:0.007056:0.005798:0.011203:0.003421:0.011118:0.005148:0.011682:0.011665:0.003421:0.003421:0.003421:0.005798:0.009168:0.011802:0.011203:0.005371:0.004738
PRRT  in  807 patients  with  neuroendocrine :@0.560581:0.250819:0.919893:0.250819:0.919893:0.236814:0.560581:0.236814:0.010126:0.010382:0.010476:0.007286:0.004738:0.003200:0.003421:0.010434:0.004738:0.003205:0.009476:0.009476:0.009476:0.007954:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.003202:0.014214:0.003421:0.005798:0.010434:0.004738:0.003202:0.010434:0.011118:0.010399:0.005073:0.011203:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.004738
tumours: the value and limitations of clini-:@0.560581:0.264613:0.915144:0.264613:0.915144:0.250607:0.560581:0.250607:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.006636:0.004738:0.006926:0.005798:0.010434:0.011118:0.006931:0.009476:0.011682:0.003421:0.010399:0.011118:0.006944:0.011682:0.010434:0.011716:0.006944:0.003421:0.003421:0.016044:0.003421:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.006944:0.011203:0.005371:0.006932:0.011067:0.003421:0.003421:0.010434:0.003421:0.005679
cal factors. :@0.560581:0.278406:0.660881:0.278406:0.660881:0.264401:0.560581:0.264401:0.011067:0.011682:0.003421:0.007748:0.005371:0.011682:0.011067:0.005798:0.011203:0.005148:0.006636:0.004738:0.004738
Eur  J  Nucl  Med  Mol  Imaging.:@0.663857:0.278406:0.915141:0.278406:0.915141:0.264401:0.663857:0.264401:0.009168:0.010399:0.005148:0.004738:0.002997:0.008244:0.004738:0.002998:0.012657:0.010399:0.011067:0.003421:0.004738:0.002997:0.015719:0.011118:0.011716:0.004738:0.002997:0.015719:0.011203:0.003421:0.004738:0.002998:0.003866:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.004738
 :@0.915141:0.278406:0.919879:0.278406:0.919879:0.264401:0.915141:0.264401:0.004738
2015;42:5-19.:@0.560581:0.292200:0.665756:0.292200:0.665756:0.278195:0.560581:0.278195:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.005679:0.009476:0.009476:0.004738
8. :@0.524235:0.305993:0.543186:0.305993:0.543186:0.291988:0.524235:0.291988:0.009476:0.004738:0.004738
  Sathekge M, :@0.560581:0.305993:0.670147:0.305993:0.670147:0.291988:0.560581:0.291988:0.004738:-0.004738:0.008518:0.011682:0.005798:0.010434:0.011118:0.008586:0.011511:0.011118:0.005605:0.015719:0.004738:0.004738
et al:@0.671024:0.305993:0.708654:0.305993:0.708654:0.291988:0.671024:0.291988:0.011118:0.005798:0.005610:0.011682:0.003421
. :@0.708654:0.305993:0.718130:0.305993:0.718130:0.291988:0.708654:0.291988:0.004738:0.004738
213:@0.719008:0.301001:0.735581:0.301001:0.735581:0.292836:0.719008:0.292836:0.005524:0.005524:0.005524
Bi-PSMA-617 targeted :@0.735587:0.305995:0.919895:0.305995:0.919895:0.291990:0.735587:0.291990:0.009818:0.003421:0.005679:0.010126:0.008518:0.015719:0.012657:0.005679:0.009476:0.009476:0.009476:0.005624:0.005798:0.011682:0.005160:0.011511:0.011118:0.005798:0.011118:0.011716:0.004738
alpha-radionuclide therapy  in metastatic :@0.560593:0.319789:0.919895:0.319789:0.919895:0.305783:0.560593:0.305783:0.011682:0.003421:0.011665:0.010434:0.011682:0.005679:0.005148:0.011682:0.011716:0.003421:0.011203:0.010434:0.010399:0.011067:0.003421:0.003421:0.011716:0.011118:0.009117:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004370:0.003421:0.010434:0.009117:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004738
castration-resistant prostate  cancer. :@0.560593:0.333582:0.870202:0.333582:0.870202:0.319577:0.560593:0.319577:0.011067:0.011682:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679:0.005073:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.008381:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738:0.003630:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Eur  J :@0.873825:0.333582:0.919892:0.333582:0.919892:0.319577:0.873825:0.319577:0.009168:0.010399:0.005148:0.004738:0.003631:0.008244:0.004738
Nucl Med Mol Imaging. :@0.560593:0.347376:0.759191:0.347376:0.759191:0.333371:0.560593:0.333371:0.012657:0.010399:0.011067:0.003421:0.004738:0.015719:0.011118:0.011716:0.004738:0.015719:0.011203:0.003421:0.004738:0.003866:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.004738:0.004738
2017;44:1099-1100.:@0.759174:0.347376:0.911728:0.347376:0.911728:0.333371:0.759174:0.333371:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
9. :@0.524246:0.361170:0.543197:0.361170:0.543197:0.347164:0.524246:0.347164:0.009476:0.004738:0.004738
  Rahbar K, :@0.560593:0.361170:0.646949:0.361170:0.646949:0.347164:0.560593:0.347164:0.004738:-0.004738:0.010382:0.011682:0.010434:0.011665:0.011682:0.005148:0.005778:0.010109:0.004738:0.004738
et al:@0.647979:0.361170:0.685779:0.361170:0.685779:0.347164:0.647979:0.347164:0.011118:0.005798:0.005781:0.011682:0.003421
. German multicenter study :@0.685779:0.361170:0.919887:0.361170:0.919887:0.347164:0.685779:0.347164:0.004738:0.005781:0.014915:0.011118:0.005620:0.016044:0.011682:0.010434:0.005781:0.016044:0.010399:0.003421:0.005798:0.003421:0.011067:0.011118:0.010434:0.005798:0.011118:0.005148:0.005771:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738
investigating :@0.560593:0.374963:0.669992:0.374963:0.669992:0.360958:0.560593:0.360958:0.003421:0.010434:0.009476:0.011118:0.006636:0.005798:0.003421:0.011511:0.011682:0.005798:0.003421:0.010434:0.011511:0.004738
177:@0.681679:0.369949:0.698252:0.369949:0.698252:0.361784:0.681679:0.361784:0.005524:0.005524:0.005524
Lu-PSMA-617  radioligand :@0.698258:0.374944:0.919884:0.374944:0.919884:0.360939:0.698258:0.360939:0.007902:0.010399:0.005679:0.010126:0.008518:0.015719:0.012657:0.005679:0.009476:0.009476:0.009476:0.004738:0.011687:0.005148:0.011682:0.011716:0.003421:0.011203:0.003421:0.003421:0.011511:0.011682:0.010434:0.011716:0.004738
therapy in advanced prostate cancer pa-:@0.560585:0.388737:0.915146:0.388737:0.915146:0.374732:0.560585:0.374732:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005653:0.003421:0.010434:0.005662:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.005662:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.005651:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005651:0.011665:0.011682:0.005679
tients. :@0.560585:0.402531:0.613266:0.402531:0.613266:0.388526:0.560585:0.388526:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
J Nucl Med.:@0.613266:0.402531:0.711821:0.402531:0.711821:0.388526:0.613266:0.388526:0.008244:0.004738:0.012657:0.010399:0.011067:0.003421:0.004738:0.015719:0.011118:0.011716:0.004738
 2017;58:85-90.:@0.711804:0.402531:0.831193:0.402531:0.831193:0.388526:0.711804:0.388526:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
10.   Fendler  WP, :@0.524238:0.416325:0.664632:0.416325:0.664632:0.402319:0.524238:0.402319:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008296:0.011118:0.010434:0.011716:0.003421:0.011118:0.005148:0.004738:0.004146:0.016420:0.008017:0.004738:0.004738
et al:@0.668787:0.416325:0.709701:0.416325:0.709701:0.402319:0.668787:0.402319:0.011118:0.005798:0.008894:0.011682:0.003421
. :@0.709701:0.416325:0.719176:0.416325:0.719176:0.402319:0.709701:0.402319:0.004738:0.004738
177:@0.723329:0.411318:0.739903:0.411318:0.739903:0.403153:0.723329:0.403153:0.005524:0.005524:0.005524
Lu-PSMA  radioligand :@0.739908:0.416313:0.919886:0.416313:0.919886:0.402308:0.739908:0.402308:0.007902:0.010399:0.005679:0.010126:0.008518:0.015719:0.012657:0.004738:0.004144:0.005148:0.011682:0.011716:0.003421:0.011203:0.003421:0.003421:0.011511:0.011682:0.010434:0.011716:0.004738
therapy for prostate cancer. :@0.560586:0.430107:0.807920:0.430107:0.807920:0.416101:0.560586:0.416101:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.007629:0.005371:0.011203:0.005148:0.007629:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.007629:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
J Nucl Med:@0.810811:0.430107:0.910410:0.430107:0.910410:0.416101:0.810811:0.416101:0.008244:0.007629:0.012657:0.010399:0.011067:0.003421:0.007629:0.015719:0.011118:0.011716
. :@0.910410:0.430107:0.919886:0.430107:0.919886:0.416101:0.910410:0.416101:0.004738:0.004738
2017;58:1196-1200.:@0.560586:0.443900:0.713140:0.443900:0.713140:0.429895:0.560586:0.429895:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
11.   Kratochwil  C, :@0.524239:0.457694:0.683230:0.457694:0.683230:0.443689:0.524239:0.443689:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010109:0.005148:0.011682:0.005798:0.011203:0.011067:0.010434:0.014214:0.003421:0.003421:0.004738:0.008027:0.013906:0.004738:0.004738
et  al:@0.691264:0.457694:0.736050:0.457694:0.736050:0.443689:0.691264:0.443689:0.011118:0.005798:0.004738:0.008029:0.011682:0.003421
. :@0.736050:0.457694:0.745525:0.457694:0.745525:0.443689:0.736050:0.443689:0.004738:0.004738
225:@0.753559:0.452688:0.770132:0.452688:0.770132:0.444522:0.753559:0.444522:0.005524:0.005524:0.005524
Ac-PSMA-617 for :@0.770138:0.457682:0.919904:0.457682:0.919904:0.443677:0.770138:0.443677:0.012657:0.011067:0.005679:0.010126:0.008518:0.015719:0.012657:0.005679:0.009476:0.009476:0.009476:0.012777:0.005371:0.011203:0.005148:0.004738
PSMA-targeted  alpha-radiation therapy :@0.560593:0.471476:0.919890:0.471476:0.919890:0.457470:0.560593:0.457470:0.010126:0.008518:0.015719:0.012657:0.005679:0.005798:0.011682:0.005148:0.011511:0.011118:0.005798:0.011118:0.011716:0.004738:0.012199:0.011682:0.003421:0.011665:0.010434:0.011682:0.005679:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.016950:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738
of  metastatic castration-resistant prostate :@0.560593:0.485269:0.919906:0.485269:0.919906:0.471264:0.560593:0.471264:0.011203:0.005371:0.004738:0.003530:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.008279:0.011067:0.011682:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679:0.005075:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.008279:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738
cancer. :@0.560593:0.499063:0.629325:0.499063:0.629325:0.485058:0.560593:0.485058:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
J Nucl Med. :@0.629325:0.499063:0.732618:0.499063:0.732618:0.485058:0.629325:0.485058:0.008244:0.004738:0.012657:0.010399:0.011067:0.003421:0.004738:0.015719:0.011118:0.011716:0.004738:0.004738
2016;57:1941-1944.:@0.732594:0.499063:0.885148:0.499063:0.885148:0.485058:0.732594:0.485058:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
12.   Parker  C, :@0.524246:0.512857:0.645477:0.512857:0.645477:0.498851:0.524246:0.498851:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.011682:0.005148:0.008586:0.011118:0.005148:0.004738:0.004955:0.013906:0.004738:0.004738
et  al:@0.650442:0.512857:0.692163:0.512857:0.692163:0.498851:0.650442:0.498851:0.011118:0.005798:0.004738:0.004964:0.011682:0.003421
.  Alph  emitter  radium-223 :@0.692163:0.512857:0.919884:0.512857:0.919884:0.498851:0.692163:0.498851:0.004738:0.004738:0.004964:0.012657:0.003421:0.011665:0.010434:0.004738:0.004965:0.011118:0.016044:0.003421:0.005798:0.005798:0.011118:0.005148:0.004738:0.004962:0.005148:0.011682:0.011716:0.003421:0.010399:0.016044:0.005679:0.009476:0.009476:0.009476:0.004738
and survival in metastatic prostate cancer. :@0.560593:0.526650:0.919897:0.526650:0.919897:0.512645:0.560593:0.512645:0.011682:0.010434:0.011716:0.005037:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.005046:0.003421:0.010434:0.005037:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.005046:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.005032:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
N Engl J Med. :@0.560593:0.540444:0.678271:0.540444:0.678271:0.526438:0.560593:0.526438:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716:0.004738:0.004738
2013;369:213-223.:@0.678254:0.540444:0.821332:0.540444:0.821332:0.526438:0.678254:0.526438:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
13.   Poeppel TD, :@0.524246:0.554237:0.665626:0.554237:0.665626:0.540232:0.524246:0.540232:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.011203:0.011118:0.011665:0.011665:0.011118:0.003421:0.005229:0.007286:0.012726:0.004738:0.004738
et al.:@0.666110:0.554237:0.708101:0.554237:0.708101:0.540232:0.666110:0.540232:0.011118:0.005798:0.005234:0.011682:0.003421:0.004738
 EANM guideline for radi-:@0.708101:0.554237:0.915149:0.554237:0.915149:0.540232:0.708101:0.540232:0.005234:0.009168:0.012657:0.012657:0.015719:0.005225:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.005234:0.005371:0.011203:0.005148:0.005225:0.005148:0.011682:0.011716:0.003421:0.005679
onuclide therapy with radium-223 of meta-:@0.560593:0.568031:0.915173:0.568031:0.915173:0.554026:0.560593:0.554026:0.011203:0.010434:0.010399:0.011067:0.003421:0.003421:0.011716:0.011118:0.004704:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004704:0.014214:0.003421:0.005798:0.010434:0.004704:0.005148:0.011682:0.011716:0.003421:0.010399:0.016044:0.005679:0.009476:0.009476:0.009476:0.004704:0.011203:0.005371:0.004693:0.016044:0.011118:0.005798:0.011682:0.005679
static castration-resistant prostate  cancer. :@0.560593:0.581825:0.919908:0.581825:0.919908:0.567819:0.560593:0.567819:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.007355:0.011067:0.011682:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679:0.005073:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.007355:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738:0.002603:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
Eur J Nucl Med Mol Imaging. :@0.560593:0.595618:0.808250:0.595618:0.808250:0.581613:0.560593:0.581613:0.009168:0.010399:0.005148:0.006058:0.008244:0.006060:0.012657:0.010399:0.011067:0.003421:0.006072:0.015719:0.011118:0.011716:0.006060:0.015719:0.011203:0.003421:0.006062:0.003866:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.004738:0.004738
Epub ahead :@0.809564:0.595618:0.919904:0.595618:0.919904:0.581613:0.809564:0.581613:0.009168:0.011665:0.010399:0.011665:0.006072:0.011682:0.010434:0.011118:0.011682:0.011716:0.004738
of print on December 12, 2017. doi:10.1007/:@0.560593:0.609412:0.915159:0.609412:0.915159:0.595407:0.560593:0.595407:0.011203:0.005371:0.003900:0.011665:0.005148:0.003421:0.010434:0.005798:0.003900:0.011203:0.010434:0.003900:0.012726:0.011118:0.011067:0.011118:0.016044:0.011665:0.011118:0.005148:0.003900:0.009476:0.009476:0.004738:0.003900:0.009476:0.009476:0.009476:0.009476:0.004738:0.003910:0.011716:0.011203:0.003421:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475
s00259-017-3900-4.:@0.560593:0.623205:0.712189:0.623205:0.712189:0.609200:0.560593:0.609200:0.006636:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
14.   Pfannkuchen N, :@0.524246:0.636999:0.699824:0.636999:0.699824:0.622994:0.524246:0.622994:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010126:0.005371:0.011682:0.010434:0.010434:0.008586:0.010399:0.011067:0.010434:0.011118:0.010434:0.007014:0.012657:0.004738:0.004738
et al:@0.702114:0.636999:0.741164:0.636999:0.741164:0.622994:0.702114:0.622994:0.011118:0.005798:0.007030:0.011682:0.003421
. Novel radiolabeled :@0.741164:0.636999:0.919887:0.636999:0.919887:0.622994:0.741164:0.622994:0.004738:0.007030:0.012657:0.011203:0.009476:0.011118:0.003421:0.007030:0.005148:0.011682:0.011716:0.003421:0.011203:0.003421:0.011682:0.011665:0.011118:0.003421:0.011118:0.011716:0.004738
bisphosphonates for  PET diagnosis and :@0.560593:0.650793:0.919894:0.650793:0.919894:0.636787:0.560593:0.636787:0.011665:0.003421:0.006636:0.011665:0.010434:0.011203:0.006636:0.011665:0.010434:0.011203:0.010434:0.011682:0.005798:0.011118:0.006636:0.013786:0.005371:0.011203:0.005148:0.004738:0.009038:0.010126:0.009168:0.007286:0.013786:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.003421:0.006636:0.013786:0.011682:0.010434:0.011716:0.004738
endoradiotherapy  of bone  metastases. :@0.560593:0.664586:0.919897:0.664586:0.919897:0.650581:0.560593:0.650581:0.011118:0.010434:0.011716:0.011203:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.009597:0.011203:0.005371:0.014351:0.011665:0.011203:0.010434:0.011118:0.004738:0.009604:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.006636:0.011118:0.006636:0.004738:0.004738
Pharmaceuticals.:@0.560593:0.678380:0.705056:0.678380:0.705056:0.664375:0.560593:0.664375:0.010126:0.010434:0.011682:0.005148:0.016044:0.011682:0.011067:0.011118:0.010399:0.005798:0.003421:0.011067:0.011682:0.003421:0.006636:0.004738
 2017;10:45. Doi: 10.3390/:@0.705056:0.678380:0.915137:0.678380:0.915137:0.664375:0.705056:0.664375:0.006294:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.006317:0.012726:0.011203:0.003421:0.004738:0.006294:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475
ph10020045.:@0.560593:0.692609:0.663236:0.692609:0.663236:0.678603:0.560593:0.678603:0.011665:0.010434:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
15.   Witzig TE, :@0.524246:0.706837:0.639423:0.706837:0.639423:0.692832:0.524246:0.692832:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.016519:0.003421:0.005798:0.007269:0.003421:0.011511:0.004960:0.007286:0.009168:0.004738:0.004738
et al:@0.639649:0.706837:0.676629:0.706837:0.676629:0.692832:0.639649:0.692832:0.011118:0.005798:0.004960:0.011682:0.003421
. Randomized controlled trial :@0.676629:0.706837:0.919894:0.706837:0.919894:0.692832:0.676629:0.692832:0.004738:0.004960:0.010382:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.004960:0.011067:0.011203:0.010434:0.005798:0.005070:0.011203:0.003421:0.003421:0.011118:0.011716:0.004960:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738
of rituximab immunotherapy  for patients :@0.560593:0.721066:0.919899:0.721066:0.919899:0.707061:0.560593:0.707061:0.011203:0.005371:0.010348:0.005148:0.003421:0.005798:0.010399:0.008210:0.003421:0.016044:0.011682:0.011665:0.010348:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.005597:0.005371:0.011203:0.005140:0.010348:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738
with relapsed or refractory low-grade, fol-:@0.560593:0.735295:0.915158:0.735295:0.915158:0.721289:0.560593:0.721289:0.014214:0.003421:0.005798:0.010434:0.007013:0.005078:0.011118:0.003421:0.011682:0.011665:0.006636:0.011118:0.011716:0.007013:0.011203:0.005148:0.007001:0.005078:0.011118:0.005371:0.005148:0.011682:0.011067:0.005798:0.011203:0.005148:0.009168:0.006996:0.003421:0.011203:0.014214:0.005679:0.011511:0.005148:0.011682:0.011716:0.011118:0.004738:0.007003:0.005371:0.011203:0.003421:0.005679
licular, or transformed B-cell non-Hodgkin’s :@0.560593:0.749523:0.919904:0.749523:0.919904:0.735518:0.560593:0.735518:0.003421:0.003421:0.011067:0.010399:0.003421:0.011682:0.003359:0.004738:0.005617:0.011203:0.005148:0.005619:0.005798:0.005148:0.011682:0.010434:0.006636:0.005371:0.011203:0.005614:0.016044:0.011118:0.011716:0.005619:0.009818:0.005679:0.011067:0.011118:0.003421:0.003421:0.005627:0.010434:0.011203:0.010434:0.005679:0.011682:0.011203:0.011716:0.011511:0.008586:0.003421:0.010434:0.006004:0.006636:0.004738
lymphoma. :@0.560593:0.763752:0.659730:0.763752:0.659730:0.749747:0.560593:0.749747:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
J Clin Oncol. :@0.658105:0.763752:0.764201:0.763752:0.764201:0.749747:0.658105:0.749747:0.008244:0.003103:0.013906:0.003421:0.003421:0.010434:0.003104:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738:0.004738
2002;20:2453-2463.:@0.762561:0.763752:0.915134:0.763752:0.915134:0.749747:0.762561:0.749747:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009495:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738